Pertuzumab and Trastuzumab Combination with Concomitant Locoregional Radiotherapy for the Treatment of Breast Cancers with HER2 Receptor Overexpression.
Pertuzumab and Trastuzumab Combination with Concomitant Locoregional Radiotherapy for the Treatment of Breast Cancers with HER2 Receptor Overexpression.
复制标题
帕妥珠单抗和曲妥珠单抗联合局部放疗治疗HER2受体过表达的乳腺癌
DOI：
10.3390/cancers13194790
复制
发表时间：
2021-09-24
期刊：
影响因子：
5.2
通讯作者：
Kirova Y
中科院分区：
文献类型：
--
作者：
Aboudaram A;Loap P;Loirat D;Dhia SB;Cao K;Fourquet A;Kirova Y
这项回顾性研究表明，局部区域乳腺RT与pertuzumab/trastuzumab双阻断HER2的联合应用具有很好的耐受性，提示在双重HER2阻断期间，RT可以安全地应用于HER2阳性乳腺癌患者。在接受放射治疗的患者中，实现了良好的局部区域控制。背景：在转移性乳腺癌患者中，联合应用派妥珠单抗和曲妥珠单抗双重HER2阻断联合相应的治疗剂量局部放射治疗是治疗策略的重要组成部分。方法：这是一项在居里研究所进行的回顾性研究，所有患者同时接受pertuzumab/trastuzumab和局部区域乳房放射治疗。毒性评价参照NCICTCAEv4.0。对最初化疗控制良好的转移性患者进行了总体生存率、无进展生存率和局部无复发生存率的评估，这些患者的局部治疗由多学科团队决定。结果：纳入2013年10月至2019年12月期间治疗的55例患者，中位随访时间为4.1年。中位年龄53岁(28-81岁)。所有患者均接受根治性剂量放射治疗(RT)，同时联合使用pertuzumab和曲妥珠单抗(pertu/trastu)。放射剂量中位数为50Gy.安全性评价未发现任何明显的不良反应，3例(5.4%)出现3级放射性皮炎，但未发现明显的胃肠道或心脏毒性。化疗前后左心室射血分数的平均差值为−2.43%(p<0.01)。结论：本研究表明局部区域乳腺RT联合PERTU/TRASTU双阻断HER2治疗的耐受性良好，提示RT可以安全地应用于HER2阳性乳腺癌患者。
This retrospective study demonstrates that the combination of locoregional breast RT with dual HER2 blockade by pertuzumab/trastuzumab was very well tolerated, suggesting that RT can be safely administered to patients with HER2-positive breast cancer during dual HER2 blockade. Excellent locoregional control was achieved in irradiated patients. Background: The combination of pertuzumab and trastuzumab dual HER2 blockade with concomitant curative dose locoregional breast radiotherapy in patients with metastatic breast cancer is an important part of treatment strategy. Methods: This was a retrospective study conducted at the Institut Curie on all patients treated concomitantly with pertuzumab/trastuzumab and locoregional breast radiotherapy. Toxicity was evaluated according to the NCICTCAEv4.0. Overall survival, progression-free survival and locoregional recurrence-free survival were evaluated in metastatic patients who were initially well controlled by chemotherapy, for whom local treatment was decided by the multidisciplinary team. Results: Fifty-five patients treated between October 2013 and December 2019 were included, with a median follow-up of 4.1 years. The median age was 53 years (range: 28–81). All patients received curative dose radiotherapy (RT) concomitantly with pertuzumab and trastuzumab (Pertu/Trastu). The median radiation dose was 50 Gy. Safety evaluation did not reveal any significant adverse effects, with 3 cases of grade 3 radiodermatitis (5.4%), but no significant gastrointestinal or cardiac toxicity. The mean difference in LVEF before any chemotherapy and after radiotherapy was −2.43% (p < 0.01). Conclusions: This study demonstrates that the combination of locoregional breast RT with dual HER2 blockade by Pertu/Trastu was very well tolerated, suggesting that RT can be safely administered to patients with HER2-positive breast cancer.
登录
查看更多内容
影响因子：
3.8
作者：
Furet, E.;Peurien, D.;Kirova, Y. M.
通讯作者：
Kirova, Y. M.
DOI：
10.1016/s1470-2045(13)70130-x
发表时间：
2013-05
期刊：
The Lancet. Oncology
影响因子：
--
作者：
Swain SM;Kim SB;Cortés J;Ro J;Semiglazov V;Campone M;Ciruelos E;Ferrero JM;Schneeweiss A;Knott A;Clark E;Ross G;Benyunes MC;Baselga J
通讯作者：
Baselga J
影响因子：
51.1
作者：
Swain, Sandra M.;Miles, David;Cortes, Javier
通讯作者：
Cortes, Javier
影响因子：
11.5
作者：
Amiri-Kordestani, Laleh;Wedam, Suparna;Cortazar, Patricia
通讯作者：
Cortazar, Patricia
影响因子：
3.7
作者：
Pons-Tostivint, Elvire;Kirova, Youlia;Dalenc, Florence
通讯作者：
Dalenc, Florence